Dr Munitta Muthana

All publications

Journal articles

• Taher Z, Legge C, Winder N, Lysyganicz P, Rawlings A, Bryant H, Muthana M & Staniland S (2021) Magnetosomes and magnetosome mimics : preparation, cancer cell uptake and functionalization for future cancer therapies. Pharmaceutics, 13(3).
• Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.. J Immunother Cancer, 9(3).
• Deng S, Iscaro A, Zambito G, Mijiti Y, Minicucci M, Essand M, Lowik C, Muthana M, Censi R, Mezzanotte L & Di Martino P (2021) Development of a new hyaluronic acid based redox-responsive nanohydrogel for the encapsulation of oncolytic viruses for cancer immunotherapy. Nanomaterials, 11(1).
• Sier VQ, de Vries MR, van der Vorst JR, Vahrmeijer AL, van Kooten C, Cruz LJ, de Geus-Oei L-F, Ferreira V, Sier CFM, Alves F & Muthana M (2021) Cell-based tracers as Trojan horses for image-guided surgery. International Journal of Molecular Sciences, 22(2).
• Aldughaim MS, Muthana M, Alsaffar F & Barker MD (2021) Specific targeting of PEGylated liposomal doxorubicin (Doxil®) to tumour cells using a novel TIMP3 peptide. Molecules, 26(1).
• George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C & Ottewell P (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 25.
• Howard F & Muthana M (2020) Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine, 15(1), 93-110.
• Niespolo C, Shologu Z, Satam S, Iscaro A, Muthana M, Socorro S, Wilson HL & Kiss-Toth E (2019) microRNAs regulating Tribbles-1: potential molecular targets in prostate cancer. European Urology Supplements, 18(8), e3090-e3091.
• Narayanan P, Martinez Campesino L, Kim T, Muthana M, Wilson HL & Kiss-Toth E (2019) Macrophage-associated changes in peri-prostatic adipose tissue; a novel local driver of prostate tumorigenesis?. European Urology Supplements, 18(8), e3060-e3060.
• Iscaro A, Howard NF & Muthana M (2019) Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
• Dorris ER, Tazzyman SJ, Moylett J, Ramamoorthi N, Hackney J, Townsend M, Muthana M, Lewis MJ, Pitzalis C & Wilson AG (2019) The Autoimmune Susceptibility Gene C5orf30 Regulates Macrophage-Mediated Resolution of Inflammation. The Journal of Immunology, 202(4), 1069-1078.
• Song W, Gregory DA, Al-janabi H, Muthana M, Cai Z & Zhao X (2019) Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. International Journal of Pharmaceutics, 555, 322-336. View this article in WRRO
• Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
• Song W, Muthana M, Mukherjee J, Falconer RJ, Biggs CA & Zhao X (2017) Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells. ACS Biomaterials Science & Engineering, 3(6), 1027-1038. View this article in WRRO
• Rahat MA, Coffelt SB, Granot Z, Muthana M & Amedei A (2016) Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer.. Mediators Inflamm, 2016, 5894347-5894347. View this article in WRRO
• Colley HE, Muthana M, Danson SJ, Jackson LV, Brett ML, Harrison J, Coole SF, Mason DP, Jennings LR, Wong M , Tulasi V et al (2015) An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. Journal of Medicinal Chemistry, 58(23), 9309-9333. View this article in WRRO
• Hawtree S, Muthana M, Wilkinson JM, Akil M & Wilson AG (2015) Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis. Human Molecular Genetics, 24(19), 5367-5377. View this article in WRRO
• Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U , Veale D et al (2015) C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 112(37), 11618-11623. View this article in WRRO
• Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M , Gonzalez-Angulo AM et al (2015) Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Research, 75(17), 3479-3491.
• Muthana M, Kennerley AJ, Hughes R, Faganano E, Richardson J, Paul M, Murdoch C, Wright F, Payne C, Lythgoe MF , Farrow N et al (2015) Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nature Communications, 6. View this article in WRRO
• Tazzyman S, Muthana M, Harrison J, Lewis C, Conner J & Chantry A (2015) Development of a Trojan horse oncolytic virus for treatment of myeloma.. Journal of Clinical Oncology, 33(15_suppl), e14035-e14035.
• Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) 233. Biological Roles of C5ORF30 in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, 53(suppl_1), i147-i147.
• Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) 79. Investigation of the Role of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, 53(suppl_1), i85-i85.
• Ellam T, Hameed A, ul Haque R, Muthana M, Wilkie M, Francis SE & Chico TJA (2014) Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice.. PLoS One, 9(2), e88767. View this article in WRRO
• Chen Y-Y, Brown NJ, Jones R, Lewis CE, Mujamammi AH, Muthana M, Seed MP & Barker MD (2014) A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice.. Angiogenesis, 17(1), 207-219. View this article in WRRO
• Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) THU0004 The Role of Histone Deacetylases in Rheumatoid Arthritis Fibroblasts-Like Synoviocytes. Annals of the Rheumatic Diseases, 72(Suppl 3), A165.4-A166.
• Hardy WJ, Aynsley S, Fearon U, Veale D, Wilson AG & Muthana M (2013) THU0107 Hypoxia-Inducible Factor 2A is Preferentially Expressed by M2-Like Synovial Macrophages in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 72(Suppl 3), A199.1-A199.
• Davies H, Muthana M, Khetan S, Adeleke G, Hawtree S, Morrow F, Ciani B & Wilson AG (2013) THU0080 The Role of C5ORF30 in Rheumatoid Arthritis Pathogenesis. Annals of the Rheumatic Diseases, 72(Suppl 3), A190.2-A190.
• Albloui FS, Muthana M, Wilson AG & Grabowski PS (2013) AB0087 Tissue localisation of acid sensing proteins in synovial biopsies from patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 72(Suppl 3), A812.2-A812.
• Hardy WJ, Aynsley S, Fearon U, Veale D, Wilson AG & Muthana M (2013) HYPDXIA-INDUCIBLE FACTOR 2A IS PREFERENTIALLY EXPRESSED BY M2-LIKE SYNOVIAL MACROPHAGES IN RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 72, 199-199.
• Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS FIBROBLASTS-LIKE SYNOVIOCYTES. ANNALS OF THE RHEUMATIC DISEASES, 72, 165-166.
• Hawtree S, Muthana M & Wilson AG (2013) The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes.. Biochem Soc Trans, 41(3), 783-788.
• Mehta P, Holder S, Fisher B, Vincent T, Nadesalingam K, Maciver H, Shingler W, Bakshi J, Hassan S, D'Cruz D , Chan A et al (2013) Case Reports * 1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGF  Receptor Mutations in Benign Joint Hypermobility. Rheumatology, 52(suppl 1), i56-i94.
• Fleischmann R, van Vollenhoven RF, Smolen J, Emery P, Florentinus S, Rathmann S, Kupper H, Kavanaugh A, Taylor P, Genovese M , Keystone EC et al (2013) Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. Rheumatology, 52(suppl 1), i44-i55.
• Muthana M, Richardson J, Rodrigues S & Lewis C (2013) Construction of Human Monocyte Derived Macrophages Armed with Oncolytic Viruses. BIO-PROTOCOL, 3(13).
• Muthana M, Rodrigues S, Chen Y-Y, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F & Lewis CE (2013) Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.. Cancer Res, 73(2), 490-495.
• Murdoch C, Aziz HA, Fang H-Y, Jezan H, Musaid R & Muthana M (2011) Khat (Catha edulis) alters the phenotype and anti-microbial activity of peripheral blood mononuclear cells.. J Ethnopharmacol, 138(3), 780-787.
• Coffelt SB, Chen Y-Y, Muthana M, Welford AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M & Lewis CE (2011) Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.. J Immunol, 186(7), 4183-4190.
• Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, Lewis CE & Byrne HM (2011) Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.. Cancer Res, 71(8), 2826-2837.
• Muthana M, Giannoudis A, Scott SD, Fang H-Y, Coffelt SB, Morrow FJ, Murdoch C, Burton J, Cross N, Burke B , Mistry R et al (2011) Use of macrophages to target therapeutic adenovirus to human prostate tumors.. Cancer Res, 71(5), 1805-1815.
• Muthana M, Multhoff G & Pockley AG (2010) Tumour infiltrating host cells and their significance for hyperthermia.. Int J Hyperthermia, 26(3), 247-255.
• Murdoch C, Muthana M, Coffelt SB & Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis.. Nat Rev Cancer, 8(8), 618-631.
• Muthana M, Scott SD, Farrow N, Morrow F, Murdoch C, Grubb S, Brown N, Dobson J & Lewis CE (2008) A novel magnetic approach to enhance the efficacy of cell-based gene therapies.. Gene Ther, 15(12), 902-910.
• Pockley AG, Muthana M & Calderwood SK (2008) The dual immunoregulatory roles of stress proteins.. Trends Biochem Sci, 33(2), 71-79.
• Pockley AG, Fairburn B, Mirza S, Slack LK, Hopkinson K & Muthana M (2007) A non-receptor-mediated mechanism for internalization of molecular chaperones.. Methods, 43(3), 238-244.
• Slack LK, Muthana M, Hopkinson K, Suvarna SK, Espigares E, Mirza S, Fairburn B & Pockley AG (2007) Administration of the stress protein gp96 prolongs rat cardiac allograft survival, modifies rejection-associated inflammatory events, and induces a state of peripheral T-cell hyporesponsiveness.. Cell Stress Chaperones, 12(1), 71-82.
• Fairburn B, Muthana M, Hopkinson K, Slack LK, Mirza S, Georgiou AS, Espigares E, Wong C & Pockley AG (2006) Analysis of purified gp96 preparations from rat and mouse livers using 2-D gel electrophoresis and tandem mass spectrometry.. Biochimie, 88(9), 1165-1174.
• Mirza S, Muthana M, Fairburn B, Slack LK, Hopkinson K & Pockley AG (2006) The stress protein gp96 is not an activator of resting rat bone marrow-derived dendritic cells, but is a costimulator and activator of CD3+ T cells.. Cell Stress Chaperones, 11(4), 364-378.
• Muthana M, Fairburn B, Mirza S, Slack LK, Hopkinson K & Pockley AG (2006) Identification of a rat bone marrow-derived dendritic cell population which secretes both IL-10 and IL-12: evidence against a reciprocal relationship between IL-10 and IL-12 secretion.. Immunobiology, 211(5), 391-402.
• Muthana M, Slack LK, Hopkinson K, Espigares E, Fairburn B, Mirza S & Pockley AG (2005) Gp96 prolongs rat cardiac allograft survival and modifies rejection-associated inflammatory events. IMMUNOLOGY, 116, 107-107.
• Mirza S, Muthana M, Slack LK, Hopkinson K, Fairburn B & Pockley AG (2005) The stress protein gp96 does not activate rat bone marrow-derived dendritic cells. IMMUNOLOGY, 116, 98-98.
• Murdoch C, Muthana M & Lewis CE (2005) Hypoxia regulates macrophage functions in inflammation.. J Immunol, 175(10), 6257-6263.
• Pockley AG & Muthana M (2005) Heat shock proteins and allograft rejection.. Contrib Nephrol, 148, 122-134.
• Muthana M, Fairburn B, Mirza S, Slack LK & Pockley AG (2004) Systematic evaluation of the conditions required for the generation of immature rat bone marrow-derived dendritic cells and their phenotypic and functional characterization.. J Immunol Methods, 294(1-2), 165-179.
• Carlring J, Shaif-Muthana M, Sisley K, Rennie IG & Murray AK (2003) Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.. Immunology, 109(1), 41-48.
• Molife R, Muthana M, Wilkinson D, Hedley S, Browne S, Brookes R, Murray A, Rennie I & Lorigan P (2002) Pilot study: Immunisation with melanoma associated peptides and GM-CSF in HLA-A2 patients with metastatic melanoma.. BRIT J CANCER, 86, S115-S115.
• Shaif-Muthana M, McIntyre C, Sisley K, Rennie I & Murray A (2000) Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.. Cancer Res, 60(22), 6441-6447.
• Murdoch C, Tazzyman S, Harrison J, Yeomans J & Muthana M () Macrophage-mediated response to hypoxia in disease. Hypoxia, 185-185. View this article in WRRO
• Kwan A, Winder NJ, Atkinson E, Al-Janabi HH, Allen RJ, Hughes R, Moamin MR, Louie R, Evans D, Hutchinson M , Capper DT et al () Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, molcanther.0748.2020-molcanther.0748.2020.

Chapters

• Hughes R & Muthana M (2014) The tumor microenvironment: The role of tumor-associated macrophages in cancer progression and responses to therapy, Tumor Immunology and Immunotherapy (pp. 43-62). Oxford University Press
• Hughes R, Fang H-Y, Muthana M & Lewis CE (2011) Role of Tumour-Associated Macrophages in the Regulation of Angiogenesis, Tumour-Associated Macrophages (pp. 17-29). Springer New York
• Pockley AG & Muthana M (2007) The Pro- and Anti-Inflammatory Properties of the Stress Protein GP96, Heat Shock Proteins: Potent Mediators of Inflammation and Immunity (pp. 309-320). Springer Netherlands
• Pockley AG & Muthana M (2007) Immunoregulatory Activities of Extracellular Stress Proteins, Cell Stress Proteins (pp. 377-395). Springer New York

Conference proceedings papers

• Danson SJ, Conner J, Edwards JG, Blyth KG, Fisher PM, Muthana M, Salawu A, Taylor F, Hodgkinson E, Joyce P , Roman J et al (2020) Oncolytic herpesvirus therapy for mesothelioma – A Phase I/IIa trial of intrapleural administration of HSV1716. Lung Cancer
• AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology
• Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
• Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
• Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
• Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
• AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology
• Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
• AL-Janabi H, Conner J, Taher Z, Staniland S & Muthana M (2018) Breast cancer immunotherapy using magnetised oncolytic viruses. European Journal of Cancer, Vol. 92 (pp S4-S4)
• Seehra RS, Wharton S, Heath P, Ince P, Muthana M, Garwood C & Simpson J (2018) Hypoxia-induced changes in astrocytes and their role in the formation of age-associated white matter lesions. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, Vol. 44 (pp 17-18)
• Dorris E, Creevey K, Moylett J, Tazzyman S, Muthana M & Wilson AG (2017) The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages. ARTHRITIS & RHEUMATOLOGY, Vol. 69
• Muthana M, Murphy E, Kwan A, Winder N & Conner J (2017) Abstract 2938: Tumour-associated macrophage polarisation and re-education with oncolytic viruses. Tumor Biology
• Dorris ER, Creevey K, Moran C, Muthana M & Wilson AG (2016) OP0134 The Rheumatoid Arthritis Susceptibility Gene C5ORF30 Acts as An Immunomodulator in Macrophages. Annals of the Rheumatic Diseases, Vol. 75(Suppl 2) (pp 107.1-107)
• Tazzyman S, Muthana M, Harrison J, Lewis C, Conner J & Chantry A (2015) Development of a Trojan horse oncolytic virus for treatment of myeloma.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 33(15)
• Hardy W, Wright F, Hawtree S, Fearon U, Veale D, Perretti M, Wilson A & Muthana M (2014) OP0296 Hypoxia-Inducible Factor 2A Regulates Macrophage Function in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 174.2-174)
• Muthana M, Davies H, Khetan S, Wright F, Hawtree S, Ciani B & Wilson A (2014) THU0515 C5orf30 A Novel Regulator of Tissue Damage in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 361.3-361)
• Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) FRI0360 Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis Synovial Fibroblasts. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 517.2-517)
• Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 85-85)
• Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 147-147)
• Albloui FS, Muthana M, Wilson AG & Grabowski PS (2014) Acidification enhances acid sensing protein and matrix metalloproteinase expression in human rheumatoid fibroblast like synoviocytes. Annals of the Rheumatic Diseases, Vol. 73(Supplement 2) (pp 511-511)
• Muthana M, Davies H, Khetan S, Adeleke G, Hawtree S, Wright F, Ciani B, Akil M & Wilson AG (2013) The biological role of C5orf30 in rheumatoid arthritis pathogenesis. IMMUNOLOGY, Vol. 140 (pp 45-45)
• Muthana M, Davies H, Khetan S, Adeleke GA, Hawtree S & Wilson AG (2013) Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1232-S1233)
• Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1035-S1036)
• Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) Investigation of the role of histone deacetylases in rheumatoid arthritis synovial fibroblasts. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 94(5) (pp A3-A3)
• Albloui FS, Muthana M, Wilson AG & Grabowski PS (2013) TISSUE LOCALISATION OF ACID SENSING PROTEINS IN SYNOVIAL BIOPSIES FROM PATIENTS WITH RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 812-812)
• Davies H, Muthana M, Khetan S, Adeleke G, Hawtree S, Morrow F, Ciani B & Wilson AG (2013) THE ROLE OF C5ORF30 IN RHEUMATOID ARTHRITIS PATHOGENESIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 190-190)
• Muthana M, Davies H, Khetan S, Adeleke G, Hawtree S, Tazzyman S, Morrow F, Ciani B & Wilson G (2013) BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 52 (pp 50-50)
• Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 52 (pp 79-80)
• Aynsley S, Hardy J, Veale D, Fearon U, Wilson G & Muthana M (2013) MACROPHAGES IN HYPOXIC RHEUMATOID JOINTS PREFERENTIALLY EXPRESS HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR-2. RHEUMATOLOGY, Vol. 52 (pp 78-78)
• Muthana M, Khetan S, Adeleke GA, Tazzyman S, Aynsley S, Morrow F, Hawtree S, Ciani B & Wilson AG (2012) Biological Roles of C5orf30 in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
• Aynsley S, Fearon U, Wilson AG & Muthana M (2012) Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
• Grabowski PS, Muthana M & Wilson AG (2012) Acid sensing protein genes are expressed in human rheumatoid-derived synoviocytes. BONE, Vol. 50 (pp S191-S191)
• Khetan S, Muthana M & Wilson AG (2011) C5orf30 a Candidate Susceptibility Gene in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 63(10) (pp S719-S719)
• Muthana M, Giannoudis A, Scott SD, Mistry R, Murdoch C, Coffelt S, Georgeopolous L, Hamdy F, Brown N, Maitland N & Lewis CE (2010) Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours. DRUG DISCOVERY TODAY, Vol. 15(23-24) (pp 1097-1098)
• Muthana M, Giannoudis A, Scott SD, Mistry R, Murdoch C, Georgeopolous L, Hamdy F, Brown N, Maitland N & Lewis CE (2010) Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours. HUMAN GENE THERAPY, Vol. 21(4) (pp 488-488)
• Muthana M, Scott S, Farrow N, Murdoch C & Lewis C (2007) Magnetite nanoparticle-loaded macrophages enhance gene delivery to tumours. IMMUNOLOGY, Vol. 120 (pp 82-82)
• Muthana M, Giannoudis A, Scott SD, Burke B, Mistry R, Hamdy F, Brown N, Maitland N & Lewis CE (2006) Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors. CANCER RESEARCH, Vol. 66(8)